Activating Mutations in Protein Tyrosine Phosphatase Ptpn11 (Shp2) Enhance Reactive Oxygen Species Production That Contributes to Myeloproliferative Disorder

被引:26
|
作者
Xu, Dan [1 ]
Zheng, Hong [1 ]
Yu, Wen-Mei [1 ]
Qu, Cheng-Kui [1 ]
机构
[1] Case Western Reserve Univ, Dept Med, Ctr Stem Cell & Regenerat Med, Div Hematol & Oncol,Case Comprehens Canc Ctr, Cleveland, OH 44106 USA
来源
PLOS ONE | 2013年 / 8卷 / 05期
基金
美国国家卫生研究院;
关键词
OF-FUNCTION MUTATION; GROWTH-FACTOR RECEPTOR; HEMATOPOIETIC STEM; MOUSE MODEL; LEUKEMIA; BINDING; GENE; MITOCHONDRIA; CHECKPOINT; DISTINCT;
D O I
10.1371/journal.pone.0063152
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Gain of function (GOF) mutations in protein tyrosine phosphatase Ptpn11 have been identified in childhood leukemias, and these mutations are sufficient to drive the development of myeloproliferative disorder and malignant leukemias in mice. However, the molecular mechanisms by which Ptpn11 mutations induce these malignancies are not completely understood. Here we report that Ptpn11 GOF mutations cause cytokine hypersensitivity in hematopoietic cells partly by enhancing the production of reactive oxygen species (ROS). GOF mutations D61G or E76K in Ptpn11 increased ROS levels in myeloid progenitors but not in hematopoietic stem cells. Increased ROS enhanced cellular responses to cytokines by promoting cytokine signaling. Treatment with an antioxidant partially corrected cytokine hypersensitivity in Ptpn11 mutant progenitors. Further analyses demonstrated that Ptpn11 mutations increased mitochondrial aerobic metabolism by interacting with a novel substrate in the mitochondria. This study provides new insights into the pathogenic effects of GOF mutations of Ptpn11 and implies that antioxidants may have a therapeutic benefit for the leukemic patients with these mutations.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] A PTPN11 Allele Encoding a Catalytically Impaired SHP2 Protein in a Patient With a Noonan Syndrome Phenotype
    Edwards, Jonathan J.
    Martinelli, Simone
    Pannone, Luca
    Lo, Ivan Fai-Man
    Shi, Lisong
    Edelmann, Lisa
    Tartaglia, Marco
    Luk, Ho-Ming
    Gelb, Bruce D.
    AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2014, 164 (09) : 2351 - 2355
  • [32] Protein Tyrosine Phosphatase Non-Receptor 11 (PTPN11/Shp2) as a Driver Oncogene and a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC)
    Richards, Cathy E.
    Elamin, Yasir Y.
    Carr, Aoife
    Gately, Kathy
    Rafee, Shereen
    Cremona, Mattia
    Hanrahan, Emer
    Smyth, Robert
    Ryan, Daniel
    Morgan, Ross K.
    Kennedy, Susan
    Hudson, Lance
    Fay, Joanna
    O'Byrne, Kenneth
    Hennessy, Bryan T.
    Toomey, Sinead
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (13)
  • [33] Inducible expression of leukemia-associated Shp2 (Ptpn11) affects multiple stages of hematopoiesis and causes a fatal myeloproliferative disorder (MPD) in mice
    Chan, Gordon
    Kalaitzidis, Demetrios
    Mohi, M. Golarn
    Yang, Wentian
    Kutok, Jeffery
    Neel, Benjamin
    BLOOD, 2007, 110 (11) : 457A - 457A
  • [34] Myeloproliferative disease induced by leukemogenic Ptpn11 (Shp-2) phosphatase arises from hematopoietic stem cells
    Xu, Dan
    Wang, Siying
    Yu, Wen-Mei
    Chan, Gordon
    Araki, Toshiyuki
    Bunting, Kevin D.
    Neel, Benjamin G.
    Qu, Cheng-Kui
    CANCER RESEARCH, 2010, 70
  • [35] Non-Lineage/Stage Restricted Effects of a Gain-of-Function Mutation in Tyrosine Phosphatase Ptpn11 (Shp2) on Malignant Transformation of Hematopoietic Cells
    Xu, Dan
    Liu, Xia
    Yu, Wen-Mei
    Meyerson, Howard J.
    Gerson, Stanton L.
    Qu, Cheng-Kui
    BLOOD, 2011, 118 (21) : 181 - 181
  • [36] Oncogenic KIT-induced aggressive systemic mastocytosis requires SHP2/PTPN11 phosphatase for disease progression in mice
    Sharma, Namit
    Everingham, Stephanie
    Zeng, Li-Fan
    Zhang, Zhong-Yin
    Kapur, Reuben
    Craig, Andrew W. B.
    ONCOTARGET, 2014, 5 (15) : 6130 - 6141
  • [37] Mutation in the gene for protein tyrosine phosphatase SHP-2 (PTPN11) in a large family with Noonan/cardio-facio-cutaneous syndrome
    Schollen, E
    Matthijs, G
    Legius, E
    Fryns, J
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2002, 10 : 238 - 238
  • [38] Noonan Syndrome/Leukemia-associated Gain-of-function Mutations in SHP-2 Phosphatase (PTPN11) Enhance Cell Migration and Angiogenesis
    Wang, Siying
    Yu, Wen-Mei
    Zhang, Wanming
    McCrae, Keith R.
    Neel, Benjamin G.
    Qu, Cheng-Kui
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (02) : 913 - 920
  • [39] PTPN11 (protein-tyrosine phosphatase, nonreceptor-type 11) mutations in seven Japanese patients with Noonan syndrome
    Kosaki, K
    Suzuki, T
    Muroya, K
    Hasegawa, T
    Sato, S
    Matsuo, N
    Kosaki, R
    Nagai, T
    Hasegawa, Y
    Ogata, T
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (08): : 3529 - 3533
  • [40] Non-lineage/stage-restricted effects of a gain-of-function mutation in tyrosine phosphatase Ptpn11 (Shp2) on malignant transformation of hematopoietic cells
    Xu, Dan
    Liu, Xia
    Yu, Wen-Mei
    Meyerson, Howard J.
    Guo, Caiying
    Gerson, Stanton L.
    Qu, Cheng-Kui
    JOURNAL OF EXPERIMENTAL MEDICINE, 2011, 208 (10): : 1977 - 1988